13-Jul-2006 - Chiltern International Limited

Chiltern is expanding its portfolio of offerings by launching its new Peri-Approval services

Peri-Approval studies begin at regulatory filing or when pivotal trials are nearing completion and extend through approval, the launch period and the remaining development life cycle of a drug. The Chiltern Peri-Approval services will cover Phase IIIb studies as well as Phase IV type studies, including Post Authorisation Safety Studies (PASS), Randomised Controlled Trials (RCTs), Outcomes and Registry studies.

"Previously, little attention was paid to Peri-Approval in Europe, although the concept has proved more popular in the US pharmaceutical market," commented Jess Sohal, who is in charge for heading up the new service. "We intend to meet the US demand for Peri-Approval services, as well as focusing on the growing need in Europe and elsewhere.

"Over the past few years, there has been a change in behaviour amongst many of the pharma companies. With the regulators focussing more and more on safety, and with less than planned new product launches Peri-Approval strategies have become more and more important. They now make up a significant part of development and augment new product launches, the earlier loss of product exclusivity and the rapid generic erosion of sales following the expiry of patents.

"Pharma companies are re-allocating their development budgets to include Peri-Approval studies to maximize their 'product assets' whilst their products are still covered by patents," she went on to explain. "Led by big pharma, the industry has adopted 'full product life cycle management' philosophies, with attached budgets to better plan their post-marketing activities.

"The EU experienced its biggest phase of enlargement in 2004 and the pharmaceutical market is still undergoing changes as a result. In the medium to long-term we envisage a particular regional increase in demand for post-marketing services. At present, the newer EU entrants are experiencing massive trans-national flows of investment from the more established European industry players. This will serve to increase the EU pharmaceutical market and create incentives for pharma to invest more in Peri-Approval activities in the accession countries."

Facts, background information, dossiers
More about Chiltern